Advertisement


Related Videos

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Deborah Collyar: What's In It for Patients?

Advertisement

Advertisement




Advertisement